The aim of this work is to evaluate the clinical improvement and the levels of interleukin 17/β-defensin-2 in saliva before and after periodontal treatment in a patient with periodontitis, rheumatoid arthritis, and psoriasis. This evidence concerns the gene IL17A and psoriasis.